CRANBURY, N.J., Jan. 31 /PRNewswire-FirstCall/ -- The Palatin Technologies, Inc. management team will hold a conference call and live audio webcast today to discuss the Company’s collaboration with AstraZeneca to discover, develop and commercialize obesity compounds. The collaboration was announced earlier this morning.
The conference call and webcast will be held today at 9:30 a.m. EST. Conference Call - Live 1/31/2007 at 9:30 a.m. EST Domestic Dial-In Number: 1-800-811-8845 International Dial-In Number: 1-913-981-4905 Conference Call - Replay 1/31 - 2/7/2007 Domestic Dial-In Number: 1-719-457-0820 International Dial-In Number: 1-888-203-1112 Replay Passcode I.D. #: 7140971
The webcast and replay can be accessed by logging on to the “Investor Center-Webcasts” section of Palatin’s website at http://www.palatin.com.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. The Company’s lead product candidate, bremelanotide, is currently in Phase II clinical trials for both male and female sexual dysfunction. The Company’s internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fuelling product development. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximise their commercial potential. To date, the Company has entered into collaborations with AstraZeneca, King Pharmaceuticals and Tyco Healthcare Mallinckrodt. For additional information regarding Palatin, please visit Palatin Technologies’ website at http://www.palatin.com.
Forward-looking Statements
Statements about the Company’s future expectations, including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin’s actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to the Company’s ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre- clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R), ability to protect its intellectual property, and other factors discussed in the Company’s periodic filings with the Securities and Exchange Commission. The Company is not responsible for updating for events that occur after the date of this press release.
Palatin Technologies, Inc.
CONTACT: Stephen T. Wills, CPA, MST, EVP-Operations / Chief FinancialOfficer of Palatin Technologies, +1-609-495-2200, or info@palatin.com; ForInstitutional Investors and Media: Carney Noensie of Burns McClellan,+1-212-213-0006, or cnoensie@burnsmc.com, for Palatin Technologies
Web site: http://www.palatin.com/
